French beauty giant L’Oréal Groupe has announced the acquisition of a majority stake in Medik8, a premium British skincare brand known for its science-backed, vitamin A-focused formulations. The deal, reportedly valued at around €1 billion, marks a strategic move to strengthen L’Oréal’s presence in the fast-growing dermatological skincare market.

Medik8, founded by scientist Elliot Isaacs, has gained a loyal following for its clinical-grade products like the Crystal Retinal serum and its signature CSA Philosophy®—Vitamin C and Sunscreen by day, Vitamin A by night. The brand will join L’Oréal’s Luxe Division, which includes names like Lancôme and SkinCeuticals.

Private equity firm Inflexion, which previously held the majority stake, will retain a minority share. Medik8’s current leadership, including CEO Simon Coble, will remain in place to ensure continuity.

“This is an exciting day for Medik8,” said Coble. “We’re joining forces with a company that shares our commitment to science, innovation, and results without compromise”.

L’Oréal’s Luxe Division has seen slower growth in recent quarters, and this acquisition is seen as a strategic boost. The company plans to begin consolidating Medik8’s sales once the deal closes, pending regulatory approvals.

With this move, L’Oréal continues its streak of targeted acquisitions aimed at bolstering its global skincare dominance, following recent deals with Korean brand Dr.G and luxury fragrance house Amouage.